Clinical Trials Browser

INDUSTRY × Interventional × lorlatinib × Clear all

Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer

NCT05144997 2025-12-17

Lorlatinib Continuation Study

Phase 4 Active not recruiting

76 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03052608 2025-11-25

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Phase 3 Active not recruiting

296 enrolled 28 charts 2 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03909971 2025-11-05

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Phase 2 Completed

109 enrolled 33 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04362072 2025-06-11

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

Phase 4 Completed

71 enrolled 26 charts

Tumor-Agnostic

Carcinoma

NCT05097599 2025-01-08

StrataPATH

Phase 2 Terminated

11 enrolled

Tumor-Agnostic

Neoplasms

NCT04541706 2024-12-20

Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

Phase 4 Completed

100 enrolled 10 charts

Thoracic

Advanced Non-Small Cell Lung Cancer

NCT04800822 2024-10-22

PF-07284892 in Participants With Advanced Solid Tumors

Phase 1 Terminated

53 enrolled

CNSGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neurofibromatosis 1, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

NCT01970865 2024-08-12

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Phase 1/2 Completed

364 enrolled 89 charts 2 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03726333 2024-06-21

Hepatic Impairment Study for Lorlatinib in Cancer Patients

Phase 1 Terminated

1 enrolled 3 charts

Thoracic

Lung Neoplasms, Neoplasms

NCT02584634 2023-07-07

Javelin Lung 101

Phase 1/2 Terminated

43 enrolled 40 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

Lorlatinib Continuation Study

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

StrataPATH

Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

PF-07284892 in Participants With Advanced Solid Tumors

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Hepatic Impairment Study for Lorlatinib in Cancer Patients

Javelin Lung 101